In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5674-5678

  Bhalodi, Amira A ^a   Crandon, Jared L ^a   Williams, Gregory ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b Cerexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; CEFTAROLINE FOSAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; INFECTION; INOCULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; POLYMICROBIAL INFECTION; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTEROIDES FRAGILIS; CEPHALOSPORINS; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; IMMUNOCOMPROMISED HOST; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 84885944382     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01162-13     Document Type: Article

References (18)

1. Dryden MS. 2010. Complicated skin and soft tissue infection. J. Antimicrob. Chemother. 65 (Suppl 3):iii35-iii44.
2. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. 2010. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 53:914-923.
3. Rao N, Lipsky BA. 2007. Optimising antimicrobial therapy in diabetic foot infections. Drugs 67:195-214.
4. Forest Laboratories, Inc. 2010. Teflaro package insert. Forest Laboratories, Inc., St. Louis, MO.
5. Ge Y, Biek D, Talbot GH, Sahm DF. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407.
6. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extendedspectrum beta-lactamases and carbapenemases. J. Antimicrob. Chemother. 62:1053-1056.
7. Sader HS, Flamm RK, Jones RN. 2013. Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. medical centers in 2010-2011. Antimicrob. Agents Chemother. 57:1982-1988.
8. Goldstein EJ, Citron DM, Merriam CV, Tyrrell KL. 2013. Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. Diagn. Microbiol. Infect. Dis. 76:347-351.
9. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
10. Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP. 2011. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:3220-3225.
11. Johnson SW, Anderson DJ, May DB, Drew RH. 2013. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum beta-lactamase-producing enterobacteriaceae on hospital admission. Infect. Control Hosp. Epidemiol. 34:385-392.
12. Reygaert WC. 2010. Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline. Ther. Clin. Risk Manag. 6:419-430.
13. Keel RA, Crandon JL, Nicolau DP. 2011. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4028-4032.
14. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
15. Bhalodi AA, Crandon JL, Williams G, Nicolau DP. 2012. Efficacy of humanized ceftaroline fosamil/avibactam exposures against Enterobacte-riaceae exhibiting MICs - 1 -g/ml. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-630.
16. Brook I. 1988. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes. J. Med. Microbiol. 27: 191-198.
17. Mastropaolo MD, Evans NP, Byrnes MK, Stevens AM, Robertson JL, Melville SB. 2005. Synergy in polymicrobial infections in a mouse model of type 2 diabetes. Infect. Immun. 73:6055-6063.
18. Ednie LM, Appelbaum PC. 2010. Comparative anti-anaerobic activity by MIC of ceftaroline (CPT) with and without NXL 104 (NXL). Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr E-801.